Introduction {#S1}
============

*Cryptosporidium* is an intracellular protozoan parasite that infects the gastrointestinal epithelium of a wide range of animals as well as humans, and causes diarrheal disease \[[@R29], [@R103]\]. Among the 38 species of *Cryptosporidium* currently recognized*, Cryptosporidium hominis* and *Cryptosporidium parvum* are responsible for the majority of human infections \[[@R43]\]. However, other species including *C. meleagridis, C. canis, C. felis*, and *C. muris* have been identified in immunocompromized patients \[[@R178]\]. Transmission of the infection is most common by the fecal-oral route, via the consumption of contaminated water and food, and contact with infected persons or animals \[[@R29]\]. Infection in immunocompetent patients is either asymptomatic or presents with profuse acute or persistent watery diarrhea, nausea and vomiting, stomach cramps, and occasionally fever that lasts approximately 2 weeks. However, in patients with immune deficiencies, the infection might cause prolonged symptoms and lead to chronic diarrhea that lasts more than 2 months, or fulminant diarrhea with more than 2 L of watery stools per day \[[@R29]\].

It is estimated that in 2016, 36.7 million people were infected with HIV worldwide. During the onset of the AIDS epidemic in the early 1980s *Cryptosporidium* became widely recognized as a human pathogen \[[@R160]\]. Diarrhea is a common problem in AIDS patients and about 30%--60% of patients in developed countries and 90% in developing countries experience diarrhea \[[@R44]\]. Diarrhea significantly influences quality of life and can lead to complications such as dehydration, malnutrition, weight loss and even death \[[@R101]\]. Cryptosporidiosis was considered one of the original AIDS-defining illnesses and a major risk factor for mortality compared to other AIDS-defining illnesses \[[@R32]\]. The prevalence of *Cryptosporidium* in immunocompetent patients varies widely, ranging from 0% to 10%, depending on country socioeconomic status \[[@R28]\]. Several studies have investigated the prevalence of *Cryptosporidium* in HIV-positive patients and have reported a wide range of estimates in different settings.

The aim of the study was to systematically review and meta-analyze the worldwide prevalence and geographic distribution of *Cryptosporidium* in HIV-positive patients and to compare the estimated prevalence using different diagnostic methods.

Methods {#S2}
=======

Search strategy and study selection {#S3}
-----------------------------------

We performed this systematic review and meta-analysis according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement \[[@R87]\]. PubMed, Science Direct, Google Scholar, Web of Science, Cochrane and Ovid databases were searched from 1 January 2000 to 31 December 2017 restricted to the English language using the following keywords: "*Cryptosporidium*", "cryptosporidiosis", "HIV", "immunodeficiency", "acquired immune deficiency syndrome", or "AIDS". After removing duplicate records, two authors independently reviewed the titles and/or abstracts of all records identified by the search. Full-texts were retrieved and evaluated for potentially relevant studies. All disagreements were resolved by consensus.

Inclusion and exclusion criteria {#S4}
--------------------------------

Studies were included in the systematic review and meta-analysis if the study was performed on HIV/AIDS patients with or without diarrhea and the prevalence of *Cryptosporidium* was evaluated using staining, antigen detection or molecular methods. Conference abstracts, animal studies, case reports, comments, and reviews were excluded. When duplicate reports of the same research were suspected, the paper reporting more relevant data was included.

Data extraction {#S5}
---------------

Data extraction was performed independently by two authors and the following information was extracted: first author, year of publication, country of study, average level of income in the country of study, region of study, study design, number of HIV/AIDS participants, sex ratio of participants, mean age, diagnostic methods, number of participants co-infected with *Cryptosporidium*, number of participants with CD4 counts \< 200 cell/mm^3^, and number of participants with diarrhea. The region of study was determined according to the WHO Global Burden of Disease Regions \[[@R176]\]. The level of income was retrieved from the 2017 World Bank classification of countries by income \[[@R175]\].

Meta-analysis {#S6}
-------------

Comprehensive meta-analysis 2.2 (Biostat Inc., USA) was used to calculate the pooled prevalence using a random-effects model. Heterogeneity was assessed using the *I*^2^ index and Cochran-Q test. An *I*^2^ index \>70% or a significant Cochran-Q test indicated heterogeneity \[[@R37]\]. Also, publication bias was assessed using Egger's intercept and visual inspection of the funnel plot. Univariate analysis was performed on the following risk factors and variables: diagnostic method, country of study, average level of income in the country of study, region of study, number of participants \>100, proportion of patients with diarrhea, and proportion of patients with low CD4 counts. Meta-regression was performed using the method of moments on the following variables: year of publication, the proportion of patients with diarrhea, and proportion of patients with low CD4 counts.

In all analyses, if a study used multiple diagnostic methods, we preferred the prevalence estimated using molecular methods to the other two, and staining methods to antigen detection methods. This procedure was implemented for all analyses except in the subgroup analysis of diagnostic methods. In these studies, all estimates of prevalence using different diagnostic methods were included. Publication bias was assessed using Egger's regression and visual inspection of the Funnel plot. A significant Egger's regression and an asymmetric Funnel plot indicated publication bias \[[@R37]\]. The level of significance for all tests was *p* \< 0.05.

Results {#S7}
=======

Search results {#S8}
--------------

After removing duplicates, titles and/or abstracts of 1986 records retrieved by the search were screened and 237 studies were selected to be reviewed in more detail using their full-texts. Of these, 161 studies fit the inclusion criteria and were included in the systematic review and meta-analysis ([Fig. 1](#F1){ref-type="fig"}).

Figure 1Flowchart describing the study design.

Characteristics of studies {#S9}
--------------------------

A total of 51,123 HIV/AIDS patients participated in these studies of which 5408 patients were co-infected with *Cryptosporidium*. The overall male to female ratio was 61.2% to 38.8% (M:F = 1.58:1) among all participants and 67.2% to 32.3% (M:F = 2.08:1) among infected participants. The mean age of participants in the included studies was 33.9 years (ranged from 10 months to 45 years). In total, studies from 40 countries worldwide were included. The countries with the most included studies were India (25%, 41/161), Ethiopia (11%, 18/161), Brazil (8%, 12/161), Nigeria and Iran (6%, 10/161). More than 40% of studies were performed in lower middle-income countries (68/161), followed by upper-middle-income countries (32%, 52/161), low-income countries (20%, 33/161) and only 5% were performed in high-income countries (8/161). Studies were also categorized based on the WHO Global Burden of Disease Regions with 33% (53/161) of studies coming from the African region, 6% (10/161) from Eastern Mediterranean countries, 3% (5/161) from the European region, 14% (23/161) from the Americas, 34% (53/161) from the South-East Asian region, and 11% (17/161) from the Western Pacific region. In terms of study design, 80% (128/161) of studies were cross-sectional, 12% (20/161) were a cohort, 7% (12/161) were case-control, and one was a case-series. Staining, antigen detection, and molecular methods were used to diagnose *Cryptosporidium* infection in 87% (140/161), 12% (19/161), and 17% (28/161) of studies, respectively ([Table 1](#T1){ref-type="table"}). Some of the studies used several methods at the same time to confirm presence of *Cryptosporidium*.

Table 1Baseline characteristics of the included studies.Paper IDFirst authorYearCountry/StateNumber of participantsNumber infectedDiagnostic methodPatients with diarrheaPatients with CD4\<200Ref.1Inungu J2000Louisiana6913239StainingNRNR\[[@R62]\]2Chokephaibulkit K2001Thailand827Ziehl-Neelsen100.00%NR\[[@R31]\]3Gassama A2001Senegal31815Ziehl-Neelsen49.70%NR\[[@R46]\]4Lebbad M2001Guinea-Bissau379Ziehl-NeelsenNRNR\[[@R85]\]5Wiwanitkit V2001Thailand602Odine and Modified Trichromes46.70%41.70%\[[@R174]\]6Brink AK2002Uganda35818Ziehl-Neelsen70.10%NR\[[@R22]\]7Joshi M2002India948Ziehl-NeelsenNRNR\[[@R70]\]8Kumar SS2002India15014Ziehl-Neelsen66.70%NR\[[@R81]\]9Leav BA2002Congo10125Ziehl-NeelsenNRNR\[[@R84]\]10Mohandas K2002India12013Ziehl-Neelsen67.50%NR\[[@R99]\]11Saksirisampant W2002Thailand15620Ziehl-NelsonNRNR\[[@R129]\]12Wanachiwanawin D2002Thailand953Ziehl-Neelsen100.00%NR\[[@R168]\]13Adjei A2003Ghana216Ziehl-Neelsen100.00%NR\[[@R4]\]14Arenas-Pinto A2003Venezuela30445Ziehl-Neelsen71.40%NR\[[@R12]\]15Cama VA2003Peru2672354Ziehl-NeelsenNRNR\[[@R23]\]16Cranendonk R2003Malawi34816Phenol-auramine-O-fluorescence49.80%NR\[[@R33]\]17Shenoy S2003India12021Ziehl-Neelsen100.00%NR\[[@R138]\]18Silva CV2003Brazil523Safranin/Methylene BlueNRNR\[[@R142]\]19Singh A2003India10047StainingNRNR\[[@R143]\]20Carcamo C2004Peru29439Modified Safranin50.00%NR\[[@R24]\]21Ribeiro PC2004Brazil757Safranin/Methylene BlueNRNR\[[@R125]\]22Zali MR2004Iran2063Ziehl-Neelsen13.60%NR\[[@R183]\]23Certad G2005Venezuela39759Ziehl-Neelsen75.60%NR\[[@R26]\]24Guk SM2005Korea677Ziehl-NeelsenNRNR\[[@R54]\]25Houpt ER2005Tanzania12722IFA48.00%NR\[[@R58]\]26Lim YA2005Malaysia662Ziehl-Neelsen9.10%NR\[[@R89]\]27Marques FR2005Brazil948Ziehl-Neelsen, ELISANRNR\[[@R91]\]28Pinlaor S2005Thailand789Ziehl-Neelsen32.10%NR\[[@R122]\]29Sadraei J2005India20084Ziehl-Neelsen38.00%41.00%\[[@R128]\]30Silva CV2005Brazil1004Safranin/Methylene Blue, ELISA38.00%NR\[[@R141]\]31Tadesse A2005Ethiopia7020Ziehl-Neelsen100.00%NR\[[@R148]\]32Tumwine JK2005Uganda9167IFANRNR\[[@R158]\]33Adhikari NA2006Nepal1126Ziehl-NeelsenNRNR\[[@R3]\]34Chhin S2006Cambodia8036Ziehl-Neelsen50.00%NR\[[@R30]\]35Navarro-i-Martinez L2006Colombia1036PCR, Ziehl-NeelsenNRNR\[[@R102]\]36Oguntibeju OO2006Lesotho606Ziehl-Neelsen56.70%NR\[[@R109]\]37Sarfati C2006Cameroon1546Ziehl-Neelsen28.60%NR\[[@R135]\]38de Oliveira-Silva MB2007Brazil35931Ziehl-Neelsen70.20%NR\[[@R36]\]39Dwivedi KK2007India7525Ziehl-Neelsen66.70%NR\[[@R40]\]40Hung CC2007Taiwan3324PCR, Ziehl-NeelsenNR40.10%\[[@R59]\]41Ramakrishnan K2007India8023Ziehl-NeelsenNRNR\[[@R124]\]42Rossit AR2007Brazil5534ELISA16.40%NR\[[@R127]\]43Stark D2007Australia62814Modified iron-hematoxylin100.00%NR\[[@R145]\]44Taherkhani H2007Iran7520Ziehl-NeelsenNRNR\[[@R149]\]45Vignesh R2007India2457Ziehl-Neelsen100.00%NR\[[@R164]\]46Bachur TP2008Brazil58247Ziehl-NeelsenNRNR\[[@R17]\]47Gupta S2008India1139Ziehl-Neelsen30.10%NR\[[@R56]\]48Jayalakshmi J2008India8911Ziehl-Neelsen, ELISA100.00%NR\[[@R68]\]49Kaushik K2008India20627PCR, Ziehl-Neelsen, ELISA48.10%32.50%\[[@R75]\]50Nuchjangreed C2008Thailand462PCR, Ziehl-Neelsen28.30%NR\[[@R107]\]51Raccurt CP2008Haiti7445PCRNRNR\[[@R123]\]52Tuli L2008India366146Ziehl-Neelsen100.00%64.50%\[[@R156]\]53Werneck-Silva AL2008Brazil6901Ziehl-NeelsenNRNR\[[@R173]\]54Zaidah AR2008Malaysia599PCR, Ziehl-NeelsenNRNR\[[@R182]\]55Zavvar M2008Iran3521PCR, Ziehl-NeelsenNRNR\[[@R184]\]56Assefa S2009Ethiopia21443Ziehl-NeelsenNRNR\[[@R14]\]57Daryani A2009Iran646Ziehl-NeelsenNRNR\[[@R34]\]58Dillingham RA2009Haiti24339Ziehl-NeelsenNR100.00%\[[@R39]\]59Gautam H2009India437ELISANR100.00%\[[@R47]\]60Kulkarni SV2009India13716Ziehl-NeelsenNR47.40%\[[@R80]\]61Kurniawan A2009Indonesia31830Ziehl-NeelsenNRNR\[[@R82]\]62Lule JR2009Uganda87930Ziehl-NeelsenNR29.90%\[[@R90]\]63Saksirisampant W2009Thailand9031PCR, Ziehl-Neelsen78.90%NR\[[@R130]\]64Uppal B2009India1003ELISA50.00%NR\[[@R161]\]65Dehkordy AB2010Iran333ELISANRNR\[[@R38]\]66Getaneh A2010Ethiopia19248Ziehl-NeelsenNRNR\[[@R49]\]67Idris NS2010Indonesia221Ziehl-NeelsenNRNR\[[@R61]\]68Kashyap B2010India648Safranin-methylene blueNR48.40%\[[@R74]\]69Tuli L2010India450163Ziehl-Neelsen100.00%NR\[[@R157]\]70Akinbo FO2011Nigeria200080Ziehl-NeelsenNR12.80%\[[@R8]\]71Alemu A2011Ethiopia18882Ziehl-NeelsenNRNR\[[@R10]\]72Cardoso LV2011Brazil5001Ziehl-Neelsen28.60%NR\[[@R25]\]73Erhabor O2011Nigeria1053Ziehl-Neelsen24.80%NR\[[@R41]\]74Kucerova Z2011Russia4619ELISANRNR\[[@R79]\]75Lim YA2011Malaysia12227Ziehl-NeelsenNRNR\[[@R88]\]76Ojurongbe O2011Nigeria9652Ziehl-NeelsenNRNR\[[@R112]\]77Patel SD2011India10020Ziehl-Neelsen32.00%NR\[[@R118]\]78Santos RB2011Brazil10104StainingNRNR\[[@R134]\]79Srisuphanunt M2011Thailand15233PCR, Ziehl-Neelsen, ELISANRNR\[[@R144]\]80Stensvold CR2011Denmark961StainingNR13.50%\[[@R146]\]81Boaitey YA2012Ghana50070Ziehl-Neelsen51.60%NR\[[@R21]\]82Iqbal A2012Malaysia34618PCRNRNR\[[@R63]\]83Izadi M2012Iran477Ziehl-NeelsenNRNR\[[@R65]\]84Jha AK2012India15487Ziehl-NeelsenNR35.10%\[[@R69]\]85Kange'the E2012Kenya1557Ziehl-NeelsenNRNR\[[@R72]\]86Khurana S2012India67140PCR, Ziehl-Neelsen, ELISANRNR\[[@R77]\]87Lehman LG2012Cameroon20113Ziehl-Neelsen18.40%NR\[[@R86]\]88Masarat S2012India4545Ziehl-Neelsen, ELISANRNR\[[@R92]\]89Netor Velasquez J2012Argentina113PCRNRNR\[[@R105]\]90Ojuromi OT2012Nigeria19344Ziehl-Neelsen34.70%NR\[[@R111]\]91Pavie J2012France1438Ziehl-Neelsen59.40%100.00%\[[@R119]\]92Roka M2012Guinea26024Ziehl-NeelsenNRNR\[[@R126]\]93Sharma P2012India97044Ziehl-NeelsenNRNR\[[@R137]\]94Tian LG2012China30225Ziehl-NeelsenNRNR\[[@R153]\]95Vyas N2012India36675Ziehl-Neelsen72.70%NR\[[@R166]\]96Wang L2013China68310PCR44.50%NR\[[@R169]\]97Adamu H2013Ethiopia37832Ziehl-Neelsen45.30%NR\[[@R2]\]98Agholi M2013Iran35634Ziehl-Neelsen28.90%52.80%\[[@R5]\]99Ahmed NH2013India24240Ziehl-NeelsenNRNR\[[@R6]\]100Akinbo FO2013Nigeria2854PCR37.90%15.80%\[[@R9]\]101Assis DC2013Brazil596Ziehl-Neelsen39.00%NR\[[@R15]\]102Ayinmode AB2013Nigeria1328PCR59.80%13.60%\[[@R16]\]103Bartelt LA2013South Africa193146ELISANRNR\[[@R18]\]104Dash M2013India11514Ziehl-NeelsenNR36.50%\[[@R35]\]105Gupta K2013India1004Ziehl-Neelsen19.00%32.00%\[[@R55]\]106Janagond AB2013India1002Ziehl-Neelsen68.00%30.00%\[[@R67]\]107Rashmi KS2013India9015Ziehl-NeelsenNRNR\[[@R71]\]108Mathur MK2013India544135Ziehl-Neelsen73.50%NR\[[@R93]\]109Mehta KD2013India1002Ziehl-NeelsenNR24.00%\[[@R94]\]110Missaye A2013Ethiopia2722Ziehl-NeelsenNR10.70%\[[@R96]\]111Mohanty I2013India25013Ziehl-Neelsen80.00%NR\[[@R100]\]112Teklemariam Z2013Ethiopia3718Ziehl-Neelsen20.20%27.00%\[[@R151]\]113Tian LG2013China798Ziehl-NeelsenNR100.00%\[[@R154]\]114Tiwari BR2013Nepal74523Ziehl-Neelsen33.30%43.90%\[[@R155]\]115Vyas N2013India7511Ziehl-NeelsenNR42.70%\[[@R167]\]116Zeynudin A2013Ethiopia918Ziehl-NeelsenNRNR\[[@R185]\]117Adamu H2014Ethiopia520140PCRNRNR\[[@R1]\]118Blanco MA2014Guinea17131PCRNRNR\[[@R20]\]119Girma M2014Ethiopia26892Ziehl-Neelsen90.30%69.80%\[[@R52]\]120Omoruyi BE2014South Africa3523PCR, Ziehl-Neelsen, ELISANRNR\[[@R113]\]121Paboriboune P2014Laos1379Ziehl-Neelsen43.10%100.00%\[[@R115]\]122Parghi E2014India9316Ziehl-NeelsenNR19.40%\[[@R117]\]123Samie A2014South Africa10630PCR, Ziehl-NeelsenNRNR\[[@R132]\]124Shimelis T2014Ethiopia25032Ziehl-NeelsenNRNR\[[@R139]\]125Taye B2014Ethiopia3163Ziehl-NeelsenNRNR\[[@R150]\]126Uppal B2014India5845PCR, Ziehl-Neelsen, ELISANR100.00%\[[@R162]\]127Vouking MZ2014Cameroon20715Ziehl-NeelsenNRNR\[[@R165]\]128Wanyiri JW2014Kenya16456PCR, Ziehl-Neelsen42.70%NR\[[@R171]\]129Ahmed NH2015India1426Ziehl-NeelsenNRNR\[[@R7]\]130Angal L2015Malaysia1315Ziehl-NeelsenNR18.30%\[[@R11]\]131Asma I2015Malaysia34643Ziehl-NeelsenNRNR\[[@R13]\]132Fregonesi BM2015Brazil174Ziehl-NeelsenNRNR\[[@R45]\]133Khalil S2015India20015Ziehl-Neelsen50.00%50.00%\[[@R76]\]134Kiros H2015Ethiopia39923Ziehl-NeelsenNR16.80%\[[@R78]\]135Mengist HM2015Ethiopia1807Ziehl-NeelsenNRNR\[[@R95]\]136Ojuromi OT2015Nigeria904PCR74.40%NR\[[@R110]\]137Oyedeji OA2015Nigeria5210Ziehl-NeelsenNRNR\[[@R114]\]138Pavlinac PB2015Kenya561Ziehl-NeelsenNRNR\[[@R120]\]139Petrincová A2015Slovak Republic200PCRNRNR\[[@R121]\]140Tellevik MG2015Tanzania338PCRNRNR\[[@R152]\]141Wumba RD2015Congo24213PCR, Ziehl-Neelsen34.30%NR\[[@R177]\]142Zhang L2015China19026ELISANR33.70%\[[@R186]\]143Gholami R2016Iran534Ziehl-Neelsen100.00%100.00%\[[@R51]\]144Hailu AW2016Ethiopia816Ziehl-NeelsenNRNR\[[@R57]\]145Kaniyarakkal V2016India2002Ziehl-Neelsen, Elisa45.50%100.00%\[[@R73]\]146Kwakye-Nuako G2016Ghana506Ziehl-NeelsenNR46.00%\[[@R83]\]147Mitra S2016India19457Ziehl-NeelsenNRNR\[[@R97]\]148Nsagha DS2016Cameroon300132Ziehl-Neelsen39.30%25.30%\[[@R106]\]149Salehi Sangani G2016Iran801Ziehl-NeelsenNR100.00%\[[@R131]\]150Shah S2016India456Ziehl-Neelsen60.00%100.00%\[[@R136]\]151Shimelis T2016Ethiopia49165Ziehl-Neelsen43.80%56.20%\[[@R140]\]152Eshetu T2017Ethiopia2237Ziehl-NeelsenNRNR\[[@R42]\]153Gedle D2017Ethiopia32319Ziehl-NeelsenNRNR\[[@R48]\]154Ghafari R2017Iran25027PCR, Ziehl-NeelsenNRNR\[[@R50]\]155Irisarri-Gutierrez MJ2017Mozambique704Ziehl-NeelsenNRNR\[[@R64]\]156Obateru O.A2017Nigeria238131Ziehl-NeelsenNRNR\[[@R108]\]157Swathirajan CR2017India82919Modified acid-fast100.00%NR\[[@R147]\]158Ukwah BN2017Nigeria25117PCR100.00%28.70%\[[@R159]\]159Uysal HK2017Turkey1153PCR, Ziehl-NeelsenNRNR\[[@R163]\]160Yang Y2017China462Modified acid-fastNRNR\[[@R180]\]161Yang Y2017China143Modified acid-fastNRNR\[[@R181]\]Abbreviations: ELISA: Enzyme-Linked Immunosorbent Assay, IFA: Immunofluorescence Assay, PCR: Polymerase Chain Reaction, NR: not reported.

Statistical analysis {#S10}
--------------------

The overall pooled prevalence of *Cryptosporidium* infection in HIV-positive patients was 14.42% (CI95%: 12.61%--16.32%). Substantial heterogeneity with an *I*^2^ of 96.4% and a significant Cochran-Q test was observed. Different diagnostic methods were utilized to detect *Cryptosporidium* infection which significantly influenced the estimated prevalence (*p* \< 0.05). The pooled prevalence was estimated to be 11.9% (CI95%: 10.2%--13.7%) using staining methods, 16.5% (CI95%: 11.1%--22.8%) using molecular methods, and 35.5% (CI95%: 21.3%--51.2%) using antigen detection methods ([Figs. 2](#F2){ref-type="fig"}--[4](#F4){ref-type="fig"}). The country of studies significantly affected the estimated pooled prevalence (*p* \< 0.05). South Africa had the highest prevalence (57.0%, CI95%: 24.4%--84.5%), while Denmark had the lowest prevalence (1.0%, CI95%: 0.1%--7.0%), although very few studies were performed in these countries. Among countries where more than ten studies were included, India had the highest prevalence (14.1%, CI95%: 10.5%--18.7%), while Brazil had the lowest prevalence (5.4%, CI95%: 2.5%--11.6%). The geographical distribution of *Cryptosporidium* and HIV co-infection is shown in [Figure 5](#F5){ref-type="fig"}.

Figure 2Forest plot diagram: The estimated pooled prevalence of *Cryptosporidium* infection in people with HIV infection by random-effect meta-analysis in included studies based on the PCR technique (first author, year of publication, and country). Note: The area of each square is proportional to the study's weight in the meta-analysis, and each line represents the confidence interval around the estimate. The diamond represents the pooled estimate.

Figure 3Forest plot diagram: The estimated pooled prevalence of *Cryptosporidium* infection in people with HIV infection by random-effect meta-analysis in included studies based on serological methods (first author, year of publication, and country). Note: The area of each square is proportional to the study's weight in the meta-analysis, and each line represents the confidence interval around the estimate. The diamond represents the pooled estimate.

Figure 4Forest plot diagram: The estimated pooled prevalence of *Cryptosporidium* infection in people with HIV infection by random-effect meta-analysis in included studies based on the staining method (first author, year of publication, and country). Note: The area of each square is proportional to the study's weight in the meta-analysis, and each line represents the confidence interval around the estimate. The diamond represents the pooled estimate.

Figure 5Pooled prevalence of *Cryptosporidium* in HIV-positive patients in different countries (source of image: <https://commons.wikimedia.org/wiki/File:BlankMap-World.svg>).

The prevalence in high-income countries was 4.1% (2.4%--6.9%), which was significantly lower than in countries with lower income (*p* \< 0.05). However, no significant difference was observed between upper-middle, lower-middle and low-income countries (*p* = 0.43). Additionally, the prevalence was not significantly different across WHO Global Burden of Disease Regions (*p* = 0.46). The South-East Asia region, with a pooled estimate of 12.7% (CI95%: 9.7%--16.4%), had the highest prevalence. Studies including less than 100 participants reported a significantly higher prevalence (15.4%, CI95%: 11.8%--19.8%) compared to the studies with more than 100 participants (8.9%, CI95%: 7.2%--11.0%). The proportion of participants with diarrhea was reported in 42% (69/161) of studies. Additionally, meta-regression showed there is no statistically significant difference within prevalence rate, depending on the year of publication (*β* intercept = −0.013, *p* = 0.50). All subgroup meta-analyses were significantly heterogeneous ([Table 2](#T2){ref-type="table"}). Among these studies, meta-analysis showed that the proportion of participants with diarrhea and CD4 counts \< 200 cells/mL significantly correlated with the pooled prevalence (*p* \< 0.0001). Similarly, the proportion of participants who received ART significantly correlated with the pooled prevalence (*p* \< 0.0001) ([Table 3](#T3){ref-type="table"}). Our study indicated that having diarrhea and having less than 200 CD4 cells μL, in HIV-infected patients, increase the risk of infection by Cryptosporidium, whereas using antiretroviral therapy in HIV-infected patients meaningfully decreases the risk of cryptosporidiosis. The funnel plot showing an asymmetric plot with studies missing on the right side and a statistically significant Egger's regression suggest the possibility of publication bias ([Fig. 6](#F6){ref-type="fig"}).

Figure 6Funnel plot of standard error by logit event rate to assess publication or other types of bias across prevalence studies.

Table 2Pooled prevalence of *Cryptosporidium* in HIV-positive patients and subgroup analyses.GroupNumber of studiesPooled prevalence (CI 95%)Heterogeneity*p*-value*p* value*I*^2^ (%)Diagnostic method*p* \< 0.05Staining14010.0% (8.4%--11.8%)\<0.00196.00Antigen detection1926.3% (15.0%--42.0%)\<0.00196.90Molecular2813.5% (8.9%--19.8%)\<0.00195.60Country[\*](#TFN1){ref-type="table-fn"}    *p* \< 0.05 Brazil125.4% (2.5%--11.6%)\<0.00193.90 China67.2% (3.5%--14.3%)\<0.00187.50 Ethiopia189.8% (6.5%--14.7%)\<0.00195.70 India4114.1% (10.5%--18.7%)\<0.00195.90 Iran1011.1% (6.0%--19.5%)\<0.00189.40 Malaysia79.1% (5.0%--15.8%)\<0.00186.60 Nigeria1110.6% (3.9%--25.6%)\<0.00198.30 Thailand811.0% (6.2%--18.7%)\<0.00185.40Region *p* = 0.46 African Region5311.9% (8.8%--16.0%)\<0.00197.00 Eastern Mediterranean Region1011.1% (6.0%--19.5%)\<0.00189.40 European Region55.4% (1.0%--23.7%)\<0.00192.00 Region of the Americas239.8% (6.4%--14.8%)\<0.00197.30 South-East Asia Region5312.7% (9.7%--16.4%)\<0.00195.50 Western Pacific Region177.7% (4.7%--12.3%)\<0.00192.60Income Level    *p* = 0.43 High income84.1% (2.4%--6.9%)\<0.00177.80 Upper-middle income5210.4% (8.0%--13.5%)\<0.00194.10 Lower-middle income6813.1% (10.2%--16.6%)\<0.00196.30 Low income3310.9% (7.6%--15.2%)\<0.00196.30Number of Participants    *p* \< 0.05 \<1006615.4% (11.8%--19.8%)\<0.00191.00 \>100958.9% (7.2%--11.0%)\<0.00197.30[^1]

Table 3Risk factors associated to *Cryptosporidium* infection in HIV patients.Risk factorsNo. of studiesCategoriesOR (95% CI)*I*² (inconsistency) %Cochran Q*p*-valueSex20Male1.11 (0.92--1.33)018.96*p* = 0.18FemaleDiarrhea44Yes3.05 (2.23--4.18)59.2105.34*p* \< 0.0001NoAntiretroviral therapy (ART)19Yes2.02 (1.19--3.41)65.351.85*p* \< 0.0001NoCD4+26\< 200 cells/ml35.84 (3.1--10.99)88207.75*p* \< 0.0001\> 200 cells/ml3Water3Boiled0.88 (0.51--1.50)01.25*p* = 0.34Tap

Discussion {#S11}
==========

Diarrhea caused by opportunistic intestinal protozoa is a common problem in HIV-infected patients. With a total number of 36 million HIV-infected patients and 11.2% prevalence of *Cryptosporidium* co-infection with HIV, approximately 4 million HIV patients are estimated to be infected with *Cryptosporidium* worldwide. The present meta-analysis of 161 studies published from 2000 to 2017 on the topic of *Cryptosporidium* infections in patients with HIV shows that the pooled worldwide prevalence of *Cryptosporidium* in patients with HIV is 14.4%. A systematic review previously assessed the worldwide prevalence of *Cryptosporidium* among patients with HIV, but did not establish the risk factors \[[@R170]\]. The prevalence of *Cryptosporidium* in the immunocompetent population has been estimated to be not more than 1% in high-income and 5%--10% in low-income countries \[[@R28]\]. In a case-control study, it was shown that HIV-positive patients had a 20-fold risk of becoming infected with *Cryptosporidium* \[[@R97], [@R98]\]. Therefore, in addition to a greater risk of developing symptomatic disease and having more severe and prolonged symptoms, patients with HIV have a greater risk of infection with *Cryptosporidium* \[[@R60]\].

Several mechanisms have been suggested to explain the susceptibility of AIDS patients to cryptosporidiosis. CD4 cells play a major role in the immune response to gastrointestinal pathogens, and it has been shown that low CD4 counts are associated with increased risk of infection with enteric parasites and chronic diarrhea \[[@R104]\]. Due to immunosuppression, symptoms of cryptosporidiosis in patients with AIDS are expressed differently in terms of severity, duration, and responses to drug treatment. It has been shown that there is a significant relationship between increased mortality rates and cryptosporidiosis in AIDS patients \[[@R19], [@R179]\]. Similarly, in the present meta-analysis, we showed that the patients with low CD4 counts had a higher prevalence rate of *Cryptosporidium* infection (*p* \< 0.0001). It seems that IFN-*γ* is associated with T-cell memory and is a critical regulator of both innate and adaptive immune responses against *Cryptosporidium* infection. Also, the findings of immunological research suggest that *Cryptosporidium* induced an inflammatory response in intestinal epithelial cells. Accordingly, the higher expression of inflammatory and pro-inflammatory cytokines, such as CXCL-10 and substance P is present in AIDS patients (compared to AIDS patients without cryptosporidiosis or negative controls) \[[@R116]\]. The opportunistic parasites *Cryptosporidium* spp. are not only associated with the immune state in HIV-infected patients, but are also more evident with antiretroviral therapy. Utilization of chemoprophylaxis could increase the immunity of HIV-positive individuals and reduce the infection. Our findings suggested that in HIV-infected patients, especially with low CD4 counts, ART should be prescribed.

Substantial heterogeneity was observed between the studies included in this meta-analysis. In addition to using the random effects model, which incorporates some of this heterogeneity, we investigated possible causes of heterogeneity and compared the estimated prevalence in different subgroups and settings \[[@R37]\]. The diagnostic method that was used to detect *Cryptosporidium* infection significantly influenced the estimated prevalence. The included studies had utilized three main categories of diagnostic methods. PCR is considered the gold standard in diagnosing *Cryptosporidium* infection with an excellent sensitivity of 97% and specificity of 100%, but is not commonly used due to its high cost and high expertise requirement, especially in low-income countries \[[@R28]\]. The estimated pooled prevalence using PCR was 16.5%, which could be considered as the "real" prevalence. Conventional microscopy, most commonly using Ziehl-Neelsen staining, is an inexpensive and widely available method but has a low sensitivity of 75% \[[@R27]\]. The estimated pooled prevalence using staining methods was 11.9%, which was the lowest estimate among used diagnostic methods. Enzyme Immunoassays (EIA), based on detection of *Cryptosporidium* antigens, cost more than the staining methods and have a moderate to high diagnostic accuracy, with a sensitivity of 75%--93%. However, confirmatory testing has been suggested when using EIA, since some false-positive reactions have been confirmed \[[@R27], [@R28], [@R172]\]. The pooled prevalence using antigen detection methods was the highest among diagnostic methods with an estimate of 35.5%. In addition to false-positive reactions, we propose that the higher prevalence in studies that utilized EIA methods could be due to possible continued shedding of *Cryptosporidium* antigens in the stools, even after the resolution of infection, although this effect has not been studied.

The geographical distribution was another confounding factor. The estimated prevalence within countries was in a range of 1% in Denmark to 57% in South Africa. Among the countries with more than ten included studies, India (14.1%), Iran (11.1%) and Nigeria (10.6%) had the highest prevalence. The economic status of different countries could be the most probable explanation for these findings. The prevalence in high-income countries, with an estimate of 4.1%, was significantly lower than in middle and low-income countries, but there was no statistically significant difference between the estimated prevalence in the middle-income and low-income countries. Additionally, the source of drinking water can contribute to the different prevalence observed within different countries. A meta-analysis showed that drinking unsafe water significantly increases the risk of *Cryptosporidium* infection \[[@R53]\]. However, we were unable to evaluate its effect on prevalence since very few studies reported the sources of drinking water. Our study showed that the pooled prevalence across WHO Global Burden of Disease regions was not significantly different.

The association of *Cryptosporidium* prevalence and the proportion of symptomatic HIV patients has been investigated. No statistically significant difference was observed between the prevalence in studies with a high proportion of symptomatic patients and studies with a low proportion of symptomatic patients, although the meta-regression showed a correlation between prevalence and the proportion of symptomatic patients. Another significant confounding variable was the number of participants in the included studies. Studies with a lower number of participants reported higher prevalence rates. This could be due to the fact that lower sample sizes are associated with higher sampling error \[[@R133]\].

The studies also differed in the period when they were conducted, but meta-regression showed that the year of publication did not correlate to estimated prevalence. A meta-analysis suggested seasonality in the prevalence of *Cryptosporidium*, and showed that precipitation and temperature are strongly associated with the rate of infection \[[@R66]\]. However, it was not possible to investigate the impact of seasons and different climates on the prevalence in the present meta-analysis, due to the limited data reported. Nonetheless, the heterogeneity after considering these confounding variables was still high. Other unknown and uninvestigated differences in study design and population might exist, but it is not uncommon for meta-analyses to have high heterogeneity. In addition to high heterogeneity, our study was also limited by the publication bias. This occurs when the results of studies influence the decision of the author or publisher. Therefore, we recommend developing a database of HIV patients infected with *Cryptosporidium* to estimate the overall prevalence of cryptosporidiosis and the geographical and time distribution of infection more accurately.

Conclusion {#S12}
==========

The prolonged and severe diarrhea caused by *Cryptosporidium* is associated with significant morbidity and mortality, especially in the HIV-infected population. This highlights the importance of preventive measures such as drinking safe water, using community-based or household water treatment systems, and education on hand hygiene after using toilets and before preparing food. Additionally, clinicians should consider early symptoms of cryptosporidiosis, such as diarrhea, in HIV patients, with the aim of initiating treatment early in the disease course. Also, patients with a CD4 count below 200 should receive prophylactic antiparasite treatment. If implemented correctly, these measures could lead to decreased morbidity, mortality, and transmission.
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[^1]: Only countries with more than 5 included studies are shown.
